All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2017-12-21T09:26:50.000Z

ASH 2017 | Interim analysis of Phase III MURANO study shows improved outcomes with venetoclax plus rituximab in patients with CLL 

Dec 21, 2017
Share:

Bookmark this article

The 59th Annual Meeting & Exposition of the American Society of Hematology (ASH) took place in Atlanta, GA, on December 9–12, 2017. On Tuesday 12th December, a late-breaking abstract session was held , with  abstract #LBA-2 being presented during this session titled “Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study” by John F Seymour Peter MacCallum Centre and Royal Melbourne Hospital, Melbourne, Australia, and colleagues.

 In a previous Phase Ib study, the combination of venetoclax and rituximab was found to be effective with acceptable safety results in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This data lead to evaluating this combination in a Phase III (MURANO) study to assess efficacy and safety compared with standard immunochemotherapy.

Study Highlights 

  • 389 eligible patients with R/R CLL were included in the study
  • Patients were randomized to receive either venetoclax with rituximab (VR) (n = 194) or bendamustine with rituximab (BR) (n = 195)
  • Median follow-up = 23.8 months (0.0–37.4)
  • Investigator-assessed (INV-assessed) progression-free survival (PFS) was superior for VR vs BR (HR = 0.17, 95%, CI 0.11–0.25, P < 0.0001)
  • Median PFS VR vs BR:
    • not reached vs0 months
  • INV-assessed overall response rate (ORR) for VR vs BR:
    • 3% vs 67.7% (Δ=25.6%, 95% CI, 17.9–33.3%)
  • Minimal residual disease negativity (MRD–) was higher with VR vs BR:
    • 5% vs 23.1%; (Δ=60.4%, 95% CI, 52.3–68.6%)
  • 2-year overall survival (OS) for VR vs BR:
    • 9% vs 86.6%; (HR = 0.48, 95% CI, 0.25–0.90, P = 0.0186)

 Safety

  • Most frequent grade 3–4 adverse events (AEs) VR vs BR:
    • Neutropenia 57.7% vs 38.8%
    • Anemia 10.8% vs 13.8%
    • Thrombocytopenia 5.7% vs 10.1%

Dr Seymour concluded that VR was superior to BR in prolonging PFS and also that this trend was consistent across the subgroup analyses. He also noted that “the secondary endpoints were in favor of venetoclax and rituximab in particular the MRD negativity rate that was maintained over time. Thus overall, venetoclax plus rituximab should be considered as a suitable standard of therapy option for patients with relapsed or refractory CLL.”

  1. Seymour JF. et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Late-breaking Abstract #LBA-2: ASH 59th Annual Meeting and Exposition, Atlanta, GA.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
44 votes - 79 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox